Diffusion modeling of percutaneous absorption kinetics: 2. Finite vehicle volume and solvent deposited solids.

The diffusion model for percutaneous absorption is developed for the specific case of delivery to the skin being limited by the application of a finite amount of solute. Two cases are considered; in the first, there is an application of a finite donor (vehicle) volume, and in the second, there are solvent-deposited solids and a thin vehicle with a high partition coefficient. In both cases, the potential effect of an interfacial resistance at the stratum corneum surface is also considered. As in the previous paper, which was concerned with the application of a constant donor concentration, clearance limitations due to the viable eqidermis, the in vitro sampling rate, or perfusion rate in vivo are included. Numerical inversion of the Laplace domain solutions was used for simulations of solute flux and cumulative amount absorbed and to model specific examples of percutaneous absorption of solvent-deposited solids. It was concluded that numerical inversions of the Laplace domain solutions for a diffusion model of the percutaneous absorption, using standard scientific software (such as SCIENTIST, MicroMath Scientific software) on modern personal computers, is a practical alternative to computation of infinite series solutions. Limits of the Laplace domain solutions were used to define the moments of the flux-time profiles for finite donor volumes and the slope of the terminal log flux-time profile. The mean transit time could be related to the diffusion time through stratum corneum, viable epidermal, and donor diffusion layer resistances and clearance from the receptor phase. Approximate expressions for the time to reach maximum flux (peak time) and maximum flux were also derived. The model was then validated using reported amount-time and flux-time profiles for finite doses applied to the skin. It was concluded that for very small donor phase volume or for very large stratum corneum-vehicle partitioning coefficients (e.g., for solvent deposited solids), the flux and amount of solute absorbed are affected by receptor conditions to a lesser extent than is obvious for a constant donor constant donor concentrations.

[1]  L. E. Matheson,et al.  Mass transport properties of co(polyether)polyurethane membranes II: permeability and sorption characteristics. , 1981, Journal of pharmaceutical sciences.

[2]  T. Franz.  The finite dose technique as a valid in vitro model for the study of percutaneous absorption in man. , 1978, Current problems in dermatology.

[3]  B. W. Barry,et al.  Penetration enhancement in human skin; effect of 2-pyrrolidone, dimethylformamide and increased hydration on finite dose permeation of aspirin and caffeine , 1984 .

[4]  H. Maibach,et al.  PENETRATION OF 14C HYDROCORTISONE THROUGH NORMAL SKIN: THE EFFECT OF STRIPPING AND OCCLUSION. , 1965, Archives of dermatology.

[5]  J. C. Jaeger,et al.  Conduction of Heat in Solids , 1952 .

[6]  D. Sir.  Re: Sunscreen Drug Products for Over-the-Counter Human Use; Monograph; Extension of Effective Date; Reopening of Administrative Record, FDA Docket No. 78N-0038 , 2000 .

[7]  M. Roberts,et al.  THE RELATIONSHIP BETWEEN STRUCTURE AND BARRIER FUNCTION OF SKIN , 1998 .

[8]  M. Roberts,et al.  Permeability of human epidermis to phenolic compounds , 1977, The Journal of pharmacy and pharmacology.

[9]  E R Cooper,et al.  Finite dose pharmacokinetics of skin penetration. , 1985, Journal of pharmaceutical sciences.

[10]  R. Scheuplein,et al.  Mechanism of percutaneous absorption. V. Percutaneous absorption of solvent deposited solids. , 1974, The Journal of investigative dermatology.

[11]  D. Guttman,et al.  Dynamic dialysis as a method for studying protein binding. I. Factors affecting the kinetics of dialysis through a cellophane membrane. , 1970, Journal of pharmaceutical sciences.

[12]  Roberts,et al.  Diffusion modeling of percutaneous absorption kinetics. 1. Effects of flow rate, receptor sampling rate, and viable epidermal resistance for a constant donor concentration. , 2000, Journal of pharmaceutical sciences.

[13]  R. Scheuplein,et al.  Mechanism of percutaneous absorption. IV. Penetration of nonelectrolytes (alcohols) from aqueous solutions and from pure liquids. , 1973, The Journal of investigative dermatology.

[14]  T. Yamada,et al.  Finite dose percutaneous drug absorption: theory and its application to in vitro timolol permeation. , 1990, Journal of pharmaceutical sciences.

[15]  H. Maibach,et al.  The effect of perfusion rate on in vitro percutaneous penetration. , 1969, The Journal of investigative dermatology.

[16]  C N Barton,et al.  Use of in vitro skin penetration data and a physiologically based model to predict in vivo blood levels of benzoic acid. , 1996, Toxicology and applied pharmacology.

[17]  R. Guy,et al.  A theoretical description relating skin penetration to the thickness of the applied medicament , 1980 .

[18]  P. P. Bhatt,et al.  Finite dose transport of drugs in liquid formulations through stratum corneum: analytical solution to a diffusion model , 1989 .

[19]  S D Gettings,et al.  Percutaneous penetration of octyl salicylate from representative sunscreen formulations through human skin in vitro. , 1997, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.